INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics
If you suffered significant losses in Pliant Therapeutics stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
New York, New York--(Newsfile Corp. - March 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ('Pliant' or the 'Company') (NASDAQ: PLRX).
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
On February 7, 2025, Pliant issued a press release 'announc[ing] that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).' Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast's path forward.
On this news, Pliant's stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025.
To learn more about the Pliant Therapeutics investigation, go to www.faruqilaw.com/PLRX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
13 minutes ago
- Business Insider
Banzai announces one-for-ten reverse stock split
Banzai (BNZI) announced that effective at market open on July 8, the company will effect a one-for-ten reverse stock split of its outstanding Class A Common Stock and Class B Common Stock. The reverse stock split is primarily intended to increase the per share price of Banzai's Class A Common Stock and maintain compliance with the Nasdaq minimum bid price requirement. The company's Class A common stock will continue to trade. Upon the effectiveness of the reverse stock split, every ten shares of issued and outstanding common stock before the open of business on July 8, will be combined into one issued and outstanding share of common stock, with no change in par value per share. The company's Class A common stock will open for trading on Nasdaq on July 8 on a post-split basis but will trade under a new CUSIP Number. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Business Insider
27 minutes ago
- Business Insider
Ree Automotive receives noncompliance letter from Nasdaq
Ree Automotive (REE) reported that the company received a letter from the Nasdaq Stock Market indicating that the company is currently not in compliance with Nasdaq Rule 5450. In particular, the letter stated that the company's closing bid price for its Class A ordinary shares has been below $1.00 per share for the last 30 consecutive business days beginning on May 15 through June 27. Nasdaq provides REE with a period of 180 calendar days to regain compliance. According to the letter, the company has until December 29 to regain compliance with the minimum bid price requirement. The company will regain compliance, if at any time during this 180-day period, the closing bid price of its ordinary shares is at least $1.00 for a minimum period of ten consecutive business days, in which case the company will be provided with a written confirmation of compliance from Nasdaq and this matter will be closed. If the company does not demonstrate compliance prior to the end of the 180-day period ending December 29, Nasdaq's staff will notify the company that its ordinary shares will be subject to delisting. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with , delivered to your inbox every week.
Yahoo
34 minutes ago
- Yahoo
Why Nektar Therapeutics Stock Dived by 3% Today
The company announced it closed its latest capital-raising effort. This took the form of a nearly 5-million strong, secondary share issue. 10 stocks we like better than Nektar Therapeutics › Nektar Therapeutics (NASDAQ: NKTR) saw its stock price erode on Thursday, following the company's closing of a secondary stock issue. Investors gave the company a thumbs-down on the news by selling out of its shares, leaving it with a 3% loss at the close of trading. Meanwhile, the benchmark S&P 500 index ticked up on the day, rising by 0.8%. Just after market hours on Wednesday, Nektar announced that it completed that new share flotation. The clinical-stage biotech sold slightly more than 4.89 million shares of its common stock. Within that number were 638,298 that were sold to the underwriters of the issue. Collectively, those entities fully exercised their option to buy Nektar stock. The gross proceeds of the issue, which was priced at $23.50 per share, amounted to roughly $115 million. Nektar wrote that it aims to deploy the new funds for "general corporate purposes," which might include drug development and manufacturing, and research and development activities. As often happens with secondary share flotations, particularly in the frequently cash-hungry biotech space, this one is notably dilutive to existing shareholders. Prior to this issue, Nektar had slightly more than 12.4 million common shares outstanding. So that nearly 5 million share-count addition is going to make a difference -- and not in a positive way. At least the money is being raised by a business with potential. Relatively speaking, Nektar has quite a few pipeline projects in development. Its leading one, rezpegaldesleukin, recently tested quite well for treating moderate-to-severe atopic dermatitis, a skin disorder. That said, the new shares are weighing on the company, and investors are probably worried that more equity offerings are coming, hence more dilution. While a company's share count shouldn't be the only consideration when evaluating a stock, it does matter, and this latest one from Nektar has sparked concern. Before you buy stock in Nektar Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nektar Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Nektar Therapeutics Stock Dived by 3% Today was originally published by The Motley Fool Sign in to access your portfolio
